Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.

O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ.

Br J Cancer. 2019 Jun;120(12):1113-1119. doi: 10.1038/s41416-019-0474-x. Epub 2019 May 20.

PMID:
31105270
2.

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.

Jones MR, Williamson LM, Topham JT, Lee MKC, Goytain A, Ho J, Denroche RE, Jang G, Pleasance E, Shen Y, Karasinska JM, McGhie JP, Gill S, Lim HJ, Moore MJ, Wong HL, Ng T, Yip S, Zhang W, Sadeghi S, Reisle C, Mungall AJ, Mungall KL, Moore RA, Ma Y, Knox JJ, Gallinger S, Laskin J, Marra MA, Schaeffer DF, Jones SJM, Renouf DJ.

Clin Cancer Res. 2019 May 8. doi: 10.1158/1078-0432.CCR-19-0191. [Epub ahead of print]

PMID:
31068372
3.

A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome.

Amin S, Rattner J, Keramati MR, Farshidfar F, McNamara MG, Knox JJ, Kopciuk K, Vogel HJ, Bathe OF.

PLoS One. 2019 Apr 2;14(4):e0213942. doi: 10.1371/journal.pone.0213942. eCollection 2019.

4.

T-bet+ memory B cells: Generation, function, and fate.

Knox JJ, Myles A, Cancro MP.

Immunol Rev. 2019 Mar;288(1):149-160. doi: 10.1111/imr.12736. Review.

PMID:
30874358
5.

Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.

Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, Jorgensen LGT, Romero JM, Bavi P, Fischer SE, Serra S, Hafezi-Bakhtiari S, Caglar D, Roehrl MHA, Cleary S, Hollingsworth MA, Petersen GM, Thayer S, Law CHL, Nanji S, Golan T, Smith AL, Borgida A, Dodd A, Hedley D, Wouters BG, O'Kane GM, Wilson JM, Zogopoulos G, Notta F, Knox JJ, Gallinger S.

Cancer Cell. 2019 Feb 11;35(2):267-282.e7. doi: 10.1016/j.ccell.2018.12.010. Epub 2019 Jan 24.

PMID:
30686769
6.

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS.

Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14.

7.

Adjuvant Therapy for Biliary Tract Cancers.

Horgan AM, Knox JJ.

J Oncol Pract. 2018 Dec;14(12):701-708. doi: 10.1200/JOP.18.00558.

PMID:
30537458
8.

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.

McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E.

Eur J Cancer. 2018 Dec;105:1-9. doi: 10.1016/j.ejca.2018.09.031. Epub 2018 Oct 29.

PMID:
30384012
9.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2019 Feb;17(1):65-71. doi: 10.1016/j.clgc.2018.09.006. Epub 2018 Sep 12.

PMID:
30341028
10.

Health-related quality of life measure distinguishes between low and high clinical T stages in esophageal cancer.

Kidane B, Ali A, Sulman J, Wong R, Knox JJ, Darling GE.

Ann Transl Med. 2018 Jul;6(13):270. doi: 10.21037/atm.2018.06.03.

11.

Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).

Murray LJ, Sykes J, Brierley J, Kim JJ, Wong RKS, Ringash J, Craig T, Velec M, Lindsay P, Knox JJ, Dawson LA.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):900-909. doi: 10.1016/j.ijrobp.2018.04.011. Epub 2018 Apr 12.

PMID:
29976502
12.

Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.

Doherty MK, Leung Y, Su J, Naik H, Patel D, Eng L, Kong QQ, Mohsin F, Brown MC, Espin-Garcia O, Vennettilli A, Renouf DJ, Faluyi OO, Knox JJ, MacKay H, Wong R, Howell D, Mittmann N, Darling GE, Cella D, Xu W, Liu G.

Dis Esophagus. 2018 Dec 1;31(12). doi: 10.1093/dote/doy058.

PMID:
29905764
13.

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.

Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1493. [Epub ahead of print]

14.

Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada.

Loveday BPT, Knox JJ, Dawson LA, Metser U, Brade A, Horgan AM, Gallinger S, Greig PD, Moulton CA.

J Surg Oncol. 2018 Feb;117(2):213-219. doi: 10.1002/jso.24833.

PMID:
29480952
15.

Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.

Grant RC, Holter S, Borgida A, Dhani NC, Hedley DW, Knox JJ, Akbari MR, Zogopoulos G, Gallinger S.

J Genet Couns. 2018 Aug;27(4):988-995. doi: 10.1007/s10897-018-0212-1. Epub 2018 Feb 13.

PMID:
29441441
16.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2018 Nov 1;29(11):2269. doi: 10.1093/annonc/mdx807. No abstract available.

17.

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.

Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ.

Clin Cancer Res. 2018 Mar 15;24(6):1344-1354. doi: 10.1158/1078-0432.CCR-17-2994. Epub 2017 Dec 29.

18.

Locally advanced pancreatic cancer: An emerging entity.

O Kane GM, Knox JJ.

Curr Probl Cancer. 2018 Jan - Feb;42(1):12-25. doi: 10.1016/j.currproblcancer.2017.10.006. Epub 2017 Nov 16. Review.

PMID:
29153290
19.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266
20.

Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma.

Pasic I, Wong KM, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown C, Bucur R, Reisman D, Knox JJ, Xu W, Hung RJ, Liu G, Cleary SP.

Mol Carcinog. 2018 Jan;57(1):106-113. doi: 10.1002/mc.22736. Epub 2017 Oct 9.

PMID:
28892201
21.

T-bet-expressing B cells during HIV and HCV infections.

Knox JJ, Kaplan DE, Betts MR.

Cell Immunol. 2017 Nov;321:26-34. doi: 10.1016/j.cellimm.2017.04.012. Epub 2017 Jul 11. Review.

22.

Long term responders to palliative chemotherapy for advanced biliary tract cancer.

Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ.

J Gastrointest Oncol. 2017 Apr;8(2):352-360. doi: 10.21037/jgo.2017.03.06.

23.

Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.

Korpanty GJ, Eng L, Qiu X, Faluyi OO, Renouf DJ, Cheng D, Patel D, Chen Z, Tse BC, Knox JJ, Dodbiba L, Teichman J, Azad AK, Wong R, Darling G, Reisman D, Cuffe S, Liu G, Xu W.

Oncotarget. 2017 Apr 25;8(17):28093-28100. doi: 10.18632/oncotarget.15890.

24.

T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Knox JJ, Buggert M, Kardava L, Seaton KE, Eller MA, Canaday DH, Robb ML, Ostrowski MA, Deeks SG, Slifka MK, Tomaras GD, Moir S, Moody MA, Betts MR.

JCI Insight. 2017 Apr 20;2(8). pii: 92943. doi: 10.1172/jci.insight.92943. eCollection 2017 Apr 20.

25.

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC.

Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16.

26.

Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.

McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, Valle JW.

BMC Cancer. 2017 Apr 12;17(1):262. doi: 10.1186/s12885-017-3266-9.

27.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075. Erratum in: Ann Oncol. 2018 Nov 1;29(11):2269.

28.

Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.

Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR.

J Hepatol. 2017 Jul;67(1):92-99. doi: 10.1016/j.jhep.2017.02.022. Epub 2017 Feb 28.

PMID:
28257902
29.

Phase I trial of radiation therapy and sorafenib in unresectable liver metastases.

Goody RB, Brade AM, Wang L, Craig T, Brierley J, Dinniwell R, Wong RKS, Cho C, Kim J, Kassam Z, Ringash J, Knox JJ, Dawson LA.

Radiother Oncol. 2017 May;123(2):234-239. doi: 10.1016/j.radonc.2017.01.018. Epub 2017 Feb 13.

PMID:
28202227
30.

Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.

Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G.

Cancer Med. 2017 Feb;6(2):361-373. doi: 10.1002/cam4.989. Epub 2017 Jan 11.

31.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

32.

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.

Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC.

Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047. Epub 2016 Oct 19.

PMID:
27771126
33.

Adjuvant therapy for resected biliary tract cancer: a review.

Doherty MK, Knox JJ.

Chin Clin Oncol. 2016 Oct;5(5):64. doi: 10.21037/cco.2016.08.05. Epub 2016 Sep 5. Review.

34.

Corrigendum: Characterization of T-bet and Eomes in Peripheral Human Immune Cells.

Knox JJ, Cosma GL, Betts MR, McLane LM.

Front Immunol. 2016 Sep 8;7:337. doi: 10.3389/fimmu.2016.00337. eCollection 2016.

35.

Pretreatment quality-of-life score is a better discriminator of oesophageal cancer survival than performance status.

Kidane B, Sulman J, Xu W, Kong Q, Wong R, Knox JJ, Darling GE.

Eur J Cardiothorac Surg. 2017 Jan;51(1):148-154. doi: 10.1093/ejcts/ezw264. Epub 2016 Aug 8.

PMID:
27506669
36.

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.

Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ.

Br J Cancer. 2016 Sep 6;115(6):649-54. doi: 10.1038/bjc.2016.222. Epub 2016 Jul 28.

37.

Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY.

Eur Urol. 2017 Feb;71(2):204-209. doi: 10.1016/j.eururo.2016.05.049. Epub 2016 Jun 16.

PMID:
27318422
38.

Baseline measure of health-related quality of life (Functional Assessment of Cancer Therapy-Esophagus) is associated with overall survival in patients with esophageal cancer.

Kidane B, Sulman J, Xu W, Kong QQ, Wong R, Knox JJ, Darling GE.

J Thorac Cardiovasc Surg. 2016 Jun;151(6):1571-80. doi: 10.1016/j.jtcvs.2016.01.052. Epub 2016 Feb 24.

39.

Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy.

Swaminath A, Knox JJ, Brierley JD, Dinniwell R, Wong R, Kassam Z, Kim J, Coolens C, Brock KK, Dawson LA.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):729-37. doi: 10.1016/j.ijrobp.2015.12.015. Epub 2015 Dec 17.

PMID:
26972645
40.

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.

Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, Heng DY.

Eur Urol. 2016 Aug;70(2):358-64. doi: 10.1016/j.eururo.2016.02.033. Epub 2016 Feb 28.

PMID:
26924770
41.

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.

Voss MH, Chen D, Marker M, Hakimi AA, Lee CH, Hsieh JJ, Knox JJ, Voi M, Motzer RJ.

Br J Cancer. 2016 Mar 15;114(6):642-9. doi: 10.1038/bjc.2016.21. Epub 2016 Feb 23.

42.

Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer.

McNamara MG, Aneja P, Le LW, Horgan AM, McKeever E, Knox JJ.

Hepatogastroenterology. 2015 May;62(139):564-9.

PMID:
26897929
43.

Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.

Mian M, McNamara MG, Doherty M, Hedley D, Knox JJ, Serra S.

J Clin Pathol. 2016 Aug;69(8):695-701. doi: 10.1136/jclinpath-2015-203397. Epub 2016 Jan 13.

PMID:
26763622
44.

Can Stereotactic Body Radiotherapy Effectively Treat Hepatocellular Carcinoma?

Barry A, Knox JJ, Wei AC, Dawson LA.

J Clin Oncol. 2016 Feb 10;34(5):404-8. doi: 10.1200/JCO.2015.64.8097. Epub 2015 Dec 23.

PMID:
26700118
45.

Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.

Horgan AM, Darling G, Wong R, Guindi M, Liu G, Jonker DJ, Lister J, Xu W, MacKay HM, Dinniwell R, Kim J, Pierre A, Shargall Y, Asmis TR, Agboola O, Seely AJ, Ringash J, Wells J, Marginean EC, Haider M, Knox JJ.

Dis Esophagus. 2016 Nov;29(8):1152-1158. doi: 10.1111/dote.12444. Epub 2015 Dec 10.

PMID:
26663741
46.

Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.

Eng L, Azad AK, Qiu X, Kong QQ, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Liu G, Faluyi OO.

Carcinogenesis. 2015 Sep;36(9):956-62. doi: 10.1093/carcin/bgv073. Epub 2015 May 25.

PMID:
26014353
47.

Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.

Grunnet M, Christensen IJ, Lassen U, Jensen LH, Lydolph M, Knox JJ, McNamara MG, Jitlal M, Wasan H, Bridgewater J, Valle JW, Mau-Sorensen M.

Eur J Cancer. 2015 Jul;51(11):1381-8. doi: 10.1016/j.ejca.2015.04.011. Epub 2015 May 9.

PMID:
25971532
48.

Localized and systemic approaches to treating hepatocellular carcinoma.

Knox JJ, Cleary SP, Dawson LA.

J Clin Oncol. 2015 Jun 1;33(16):1835-44. doi: 10.1200/JCO.2014.60.1153. Epub 2015 Apr 27. Review. No abstract available.

PMID:
25918289
49.

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA.

J Immunother Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.

50.

Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.

Seah JA, Leibowitz-Amit R, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM, Sridhar SS.

Clin Genitourin Cancer. 2015 Aug;13(4):e229-e233. doi: 10.1016/j.clgc.2015.02.001. Epub 2015 Feb 7.

PMID:
25777682

Supplemental Content

Support Center